Annual Report

The report describes Evotec’s 2020 expansion of its data-driven, multimodality R&D strategy, including gene therapy and antisense therapy, and the construction of its first J.POD facility. Group revenues increased 12% to € 500.9 m, while year-end employee headcount was 3,572. Evotec reported joining SBTi and committing to reduce its CO2 footprint. The report also describes a sustainability readiness and materiality process.